
Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) – Research analysts at HC Wainwright raised their FY2026 earnings estimates for Vir Biotechnology in a research note issued to investors on Monday, November 9th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.89) for the year, up from their prior forecast of ($1.89). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.99) EPS.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.18. The business had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.98 million. The business’s revenue for the quarter was down 178.3% on a year-over-year basis. During the same period last year, the firm earned ($1.17) EPS.
Check Out Our Latest Stock Analysis on Vir Biotechnology
Vir Biotechnology Trading Down 7.7%
VIR opened at $12.12 on Wednesday. Vir Biotechnology has a 12 month low of $5.32 and a 12 month high of $14.38. The company has a market cap of $2.08 billion, a PE ratio of -9.62 and a beta of 1.70. The company has a 50 day moving average of $11.18 and a 200 day moving average of $9.73.
Insider Activity at Vir Biotechnology
In related news, EVP Vanina de Verneuil sold 2,407 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total transaction of $26,717.70. Following the completion of the transaction, the executive vice president directly owned 110,193 shares in the company, valued at $1,223,142.30. The trade was a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is owned by company insiders.
Institutional Trading of Vir Biotechnology
A number of large investors have recently modified their holdings of the business. Fiduciary Financial Advisors bought a new position in shares of Vir Biotechnology in the second quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Vir Biotechnology during the third quarter valued at approximately $97,000. Caxton Associates LLP purchased a new position in Vir Biotechnology in the 1st quarter worth approximately $112,000. Amundi grew its stake in Vir Biotechnology by 52.8% in the 1st quarter. Amundi now owns 15,315 shares of the company’s stock worth $137,000 after buying an additional 5,294 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in Vir Biotechnology by 223.1% in the 1st quarter. Royal Bank of Canada now owns 15,355 shares of the company’s stock worth $138,000 after buying an additional 10,603 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.
More Vir Biotechnology News
Investors following VIR have been watching these news items:
- Positive Sentiment: Analysts remain constructive: Morgan Stanley expects the stock to rise, while H.C. Wainwright, Bank of America Securities, Evercore ISI and TD Cowen maintained Buy ratings. H.C. Wainwright’s reported price target is $22. Morgan Stanley analyst outlook H.C. Wainwright rating Bank of America Securities rating Evercore ISI rating TD Cowen rating
- Neutral Sentiment: A valuation-focused article asks whether VIR is overvalued after a reported 127% run, highlighting that the strong recent rally may prompt investors to reassess its valuation. Valuation discussion
- Negative Sentiment: Vir announced a proposed underwritten public offering of common stock and may give underwriters a 30-day option to buy up to 15% more shares. The added share supply could dilute existing ownership and weigh on the stock; the offering size and pricing were not specified in the announcement. Offering announcement
About Vir Biotechnology
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments. The company’s pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs.
Read More
- Five stocks we like better than Vir Biotechnology
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
